Answers are grounded in this paper and cite their sources.
The aim of this study was to evaluate the possibility of improving the intestinal environment by reducing intestinal pathogens, Staphylococcus aureus and Escherichia coli, using the three Levilactobacillus brevis strains (L. brevis KU202399, L. brevis B151, and L. brevis KU15006) isolated from kimchi. We confirmed the characteristics of the probiotics and the safety of the L. brevis strains. Also, we examined the antibacterial effects, cell surface properties, anti-adhesion ability, and expression of antibiotic resistance and toxicity genes. L. brevis KU202399 exhibited the highest antibacterial activity; L. brevis KU202399 exhibited high cell surface hydrophobicity and decreased adhesion ability of pathogens to intestinal cells. Real-time polymerase-chain reaction results showed significant downregulated expression of antibiotic resistance and toxicity-related gene treatment with L. brevis KU202399. L. brevis KU202399 modulated human fecal microbiota by increasing beneficial bacteria and reducing pathogens. Taken together, our results suggest that L. brevis KU202399 is beneficial in food and probiotic industries.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: